Review of new lipid formulations of amphotericin B;Nouvelles formes lipidiques de l'amphotéricine B. Revue de la littérature

Revue de Medecine Interne

Volumn 22, Issue 2, 2001, Pages 141-150

  Andres E ^a   Tiphine, M ^b   Letscher Bru, V ^c   Herbrecht, R ^a  

^a HÔPITAL DE HAUTEPIERRE   (France)

^b Pharmacie   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Amphotericin B; Amphotericin B colloidal dispersion; Amphotericin B in fat emulsion; Amphotericin B lipid complex; Invasive fungal infections; Liposomal amphotericin B

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; FLUCYTOSINE; INTRALIPID;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG SAFETY; FUNGAL MENINGITIS; HUMAN; MAJOR CLINICAL STUDY; MUCORMYCOSIS; MYCOSIS; NEPHROTOXICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL;

EID: 0035121778     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0248-8663(00)00304-0     Document Type: Article

References (85)

1. Amphotericin B: 30 Years of clinical experience
2. Carrier effects on biological activity of amphotericin B
3. Involvement of oxydative damage in erythrocyte lysis induced by amphotericin B
4. The effects of azole and polyene anti-fungals on the plasma membrane enzymes of Candida albicans
5. Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion
6. In vitro activities of polyene and imidazole antifungal agents against unusual opportunistic fungal pathogens
7. New emerging fungal pathogens
8. Comparative safety, tolerance and pharmacokinetics of amphotericin B lipid complex and amphotericin B deoxycholate in healthy male volunteers
9. Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers
10. Amphotericin B pharmacokinetics in humans
11. Distribution and activity of amphotericin B in humans
12. Administering amphotericin B: A practical approach
13. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patient without neutropenia
14. International conference for the development of a consensus on the management and prevention of severe candidal infections
15. Treatment of invasive aspergillosis
16. Traitement curatif de l'aspergillose pulmonaire invasive
17. Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid® for the treatment of AIDS-associated cryptococcal meningitis
18. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome
19. Mucormycosis in the BMT population
20. Survival factors in rhino-orbital-cerebral mucormycosis
21. Trichosporon infections: Clinical manifestations and treatment
22. Pharmacologic modulation of interleukin-1 expression by amphotericin B-stimulated human mononuclear cells
23. Pretreatment regimens for adverse events related to infusion of amphotericin B
24. Efficacy of nefopam for the prevention and treatment of amphotericin B-induced shivering
25. Rapid infusion of amphotericin B in dextrose
26. Rapid intravenous infusion of amphotericin B: A pilot study
27. Amphotericin B revisited: Re-assessment of toxicity
28. Direct vasoconstriction as a possible cause for amphotericin B-induced nephrotoxicity in rats
29. Must we really fear toxicity of conventional amphotericin B in oncological patients?
30. Effect of salt supplementation on amphotericin B nephrotoxicity
31. Amphotericin B lipid complex: Review of safety, phamacokinetics and efficacy
32. Lipid formulations of amphotericin B: Clinical efficacy and toxicities
33. Tissue distribution of amphotericin B lipid complex in laboratory animals
34. In vitro and in vivo antifungal activity of amphotericin B lipid complex: Are phospholipases important?
35. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases
36. Efficacy of amphotericin B lipid complex (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses
37. Amphotericin B lipid complex in pediatric patients with invasive fungal infections
38. Amphotericin B lipid complex versus amphotericin B for the treatment of hematogenous and invasive candidiasis: A prospective randomized multicenter trial
39. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS
40. Renal effects of amphotericin B lipid complex
41. Liposomal amphotericin B, Ambisome®
42. Ambisome® (liposomal amphotericin B): A comparative review
43. Safety, tolerance and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (Ambisome®) in neutropenic patients
44. Ambisome®: An overview of current use
45. Efficacy of amphotericin B encapsuled in liposomes (Ambisome®) in the treatment of invasive fungal infections in immunocompromised patients
46. Prophylaxis and therapy using liposomal amphotericin B (Ambisome®) for invasive fungal infections in children undergoing organ or allogenic bone-marrow transplantation
47. A randomized comparison of liposomal versus conventional amphotericin B for treatment of pyrexia of unknown origin in neutropenic patients
48. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
49. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections
50. Liposomal amphotericin B (Ambisome®) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis
51. An EORTC international multicenter randomized trial (EORTC 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis
52. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study
53. Prophylactic use of liposomal amphotericin B (Ambisome®) against fungal infections: A randomized trial in bone marrow transplant recipients
54. Liposomal amphotericin (Ambisome®) in the prophylaxis of fungal infections in neutropenic patients: A randomized, double-blind, placebo-controlled study
55. US Food and Drug Administration approval of Ambisome® (liposomal amphotericin B) for treatment of visceral leishmaniasis
56. A randomized double-blind safety study of Ambisome® and Abelcet® in febrile neutropenic patients
57. Overview of amphotericin B colloidal dispersion (Amphocil®)
58. Safety and efficacy of amphotericin B colloidal dispersion. An overview
59. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis
60. Zygomycosis treated with amphotericin B colloidal dispersion. A review of 22 cases
61. A double-blind clinical trial of Amphocil® versus amphotericin B in invasive aspergillosis in immunocompromised patients
62. Randomized double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia
63. Amphotericin B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis
64. Treatment of visceral leishmaniasis with amphotericin B colloidal dispersion
65. Renal sparing by amphotericin B colloidal dispersion: Clinical experience in 572 patients
66. Treatment with high cumulative doses of amphotericin B colloidal dispersion. Efficacy and tolerance in 96 patientsBlood
67. Amphotéricine B: Ancien médicament, nouveaux concepts
68. A comparative review of conventional and lipid formulations of amphotericin B
69. An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis
70. In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone®) associated with Intralipid®
71. Amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS-patients
72. Amphotéricine B désoxycholate (Fungizone®): Vieux médicament, nouvelles versions
73. Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B
74. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis
75. Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia
76. Pharmacological parameters in intravenously administered amphotericin B in rats: Comparison of the conventional formulation with amphotericin B associated with a triglyceride-rich emulsion
77. Antifungal activity of amphotericin B-lipid admixtures in experimental systemic candidosis in native mice
78. In-vivo activity and tolerance of conventional formulation versus fat emulsion formulation of amphotericin B in experimental disseminated candidiasis in neutropenic rabbits
79. Aspergillose pulmonaire invasive: Intérêt d'un traitement par amphotéricine B administrée dans une solution de triglycérides à usage parentéral
80. Comparison of glucose versus fat emulsion in the preparation of amphotericin B for use in Kala-Azar
81. A retrospective study on the efficacy and safety of amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients
82. Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients
83. Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: Results of a prospective, randomized, controlled study in critically ill patients
84. A randomized prospective trial of amphotericin B lipid emulsion versus dextrose colloidal solution in critically ill patients
85. Safety and toxicity of amphotericin B in glucose 5% or Intralipid® 20% in neutropenic patients with pneumonia or fever of unknown origin: Randomized study